No Data
No Data
Express News | Polyrizon Shares Are Trading Higher After the Company Announced It Filed a Patent Application for a Trap & Target Intranasal Drug Delivery Platform
Polyrizon Files Divisional Patent Application With Israel Patent Office
Polyrizon Ltd. Files Divisional Patent Application for Trap & Target Platform Technology Enhancing Intranasal Drug Delivery
Polyrizon Preparing For Clinical Trial Of PL-14 In 2025
Polyrizon Partners With Eurofins CDMO Amatsiaquitaine S.A.S. for GMP Manufacturing Support Ahead of 2025 Clinical Trial
Polyrizon Commences GMP Manufacturing Preliminary Process for Its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial